Cipla USA Inc. secured FDA approval for its generic oral tablet of Dapagliflozin, positioning the manufacturer to capture market share in the growing diabetes treatment sector. This approval allows the company to compete directly with branded therapies by offering a more cost-effective alternative to patients and providers.